Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program
Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Acronyms CLINIVO
- 05 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2017 Results (n=600, data cut off: Aug 2015) presented at the 42nd European Society for Medical Oncology Congress